Clovis Oncology (CLVS) Announces FDA Acceptance of Rucaparib NDA for Priority Review
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Clovis Oncology (CLVS) PT Raised to $19 at Credit Suisse as Priority Review/Label Are Best Case Scenario
August 24, 2016 7:34 AM EDTCredit Suisse analyst K. MacKay reiterated a Neutral rating and raised its price target on Clovis Oncology (NASDAQ: CLVS) to $19.00 (from $14.00) announced the FDA has accepted its rucaparib NDA submission in 3L g/sBRCA+ ovarian cancer and has been granted priority review with a Feb 23, 2017 PDUFA date. The firm views the... More
Mizuho Boosts PT on Clovis Oncology (CLVS) to $23 Following Rucaparib NDA Approval
August 24, 2016 6:34 AM EDTMizuho boosts its price taget on Neutral-rated Clovis Oncology (Nasdaq: CLVS) from $15 to $23 after the company announced that the U.S. Food and Drug Administration (FDA) has accepted Clovis New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to... More
Stifel Affirms Clovis Oncology (CLVS) at 'Buy'; Sees Rucaparib Approval in Q117
August 24, 2016 6:14 AM EDTStifel affirms Clovis Oncology (Nasdaq: CLVS) with a Buy rating and $30 price target after the company announced that the U.S. Food and Drug Administration (FDA) has accepted... More
Clovis Oncology (CLVS) Halted on LUDP
August 23, 2016 2:32 PM EDTClovis Oncology (NASDAQ: CLVS) Halted on LUDP
... More